LBA2 The DANTE phase III trial comparing 1 year versus 2 years of anti-PD1 immunotherapy as first-line treatment for metastatic melanoma: Health economics analysis

Metadata

Item Type:	Conference or Workshop Item
Authors/Creators:	Gkountouras, G. https://orcid.org/0000-0003-2093-5359 Meads, D. Mujica-Mota, R. Collinson, M. https://orcid.org/0000-0003-3568-6455 Plummer, R. Ottensmeier, C.H.H. Silva, S.C. Hook, J.M. Hapuarachi, B.B. Wheater, M. Payne, M. Oladipo, O. Waterston, A. Bell, S. Greatorex, N. Katona, E. Daniels, S. Corrie, P.G. Danson, S.
Copyright, Publisher and Additional Information:	This is an open access conference abstract under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Dates:	Published (online): 26 December 2025 Published: 26 December 2025
Institution:	The University of Leeds
Academic Units:	The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Date Deposited:	15 Jan 2026 13:05
Last Modified:	15 Jan 2026 13:05
Published Version:	https://www.sciencedirect.com/science/article/pii/...
Status:	Published
Publisher:	Elsevier
Identification Number:	10.1016/j.iotech.2025.101552
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:236157

CORE (COnnecting REpositories)